March 2015

ACRES Blue Cloud IT Platform provides shared interface for clinical researchers

Monday, March 30, 2015

The Alliance for Clinical Research Excellence and Safety (ACRES), a Cambridge, Mass.-based clinical research nonprofit organization, has launched ACRES BlueCloud, the first phase implementation of a shared multi-user interface to allow sponsors, CROs, regulatory agencies, funding agencies and IRBs to access millions of verifiable professional experience and training credentials, enabling long-sought sharing and mutual recognition of those credentials by multiple stakeholders.

[Read More]

AcelRx restructures, reduces workforce 36%

Monday, March 30, 2015

AcelRx Pharmaceuticals, a California-based specialty pharma focused on development and commercialization of innovative therapies for the treatment of acute pain, has restructured its work force as part of a plan to reduce operating costs and focus its financial and development resources on working with the FDA to seek marketing approval for Zalviso, as well as to continue the development of ARX-04.

[Read More]

NIH awards $9M to speed development of health technologies

Monday, March 30, 2015

The NIH has selected three new proof-of-concept hubs to help speed the translation of basic biomedical discoveries into commercial products, such as new drugs, devices and diagnostics, to improve patient care and enhance health. The hubs are part of the NIH-supported Research Evaluation and Commercialization Hubs (REACH) program and will be funded $9 million over three years.

[Read More]

Veeva launches OpenKey, partner program to unlock difficult access to, restrictions on customer reference data

Monday, March 30, 2015

Having accurate customer reference data for all healthcare professionals, healthcare organizations and affili­ations across life sciences’ major markets—and managing it all—is a burden Veeva Systems has addressed with the launch of a new streamlined approach to deliver cus­tomer data sourced locally and consolidated into a single global reference database.

[Read More]

Why we need more older patients in clinical trials

Monday, March 30, 2015

The Pulse on Global Trials by Matthew Howes

As our population ages and medical advances increase life expectancy, drug developers are facing an emerging gap in clinical research: lack of evidence to guide treatment decisions for people over 65.

[Read More]

Vtesse forms scientific advisory board

Friday, March 27, 2015

Vtesse, a rare disease company focused on developing drugs for Niemann-Pick Disease Type C (NPC) and other severe diseases with great unmet need, has formed its scientific advisory board (SAB). Comprising experts from a range of fields including pediatrics, translational medicine, biomarker research and genetics, the SAB will advise on clinical and regulatory strategy as well as product development for the company’s lead candidate, VTS-270.

[Read More]

Parkinson’s Biomarker Initiative expands genetic study

Friday, March 27, 2015

The Parkinson’s Progression Markers Initiative (PPMI), a large-scale biomarker study sponsored by the Michael J. Fox Foundation for Parkinson’s Research (MJFF), is expanding to study individuals with a mutation of the GBA (glucosidase beta acid) gene. Participants will include people with or at increased risk to develop Parkinson’s disease. Researchers hope that a greater understanding of the biology and clinical features of these participants will lead to therapies benefiting all Parkinson’s patients and ultimately provide strategies to prevent disease onset.

[Read More]